Edward Hernandez, MD
Ophthalmology · Las Cruces, NMNPI 1346263126
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Alcon at 40.7% of the total. Reporting peaked in 2021 at $921 and has fallen 70.9% since, to $268 in 2025.
Across 123 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$670
- Shire North American Group Inc$142
- Bausch & Lomb Americas Inc.$138
- Bausch & Lomb, A Division Of Bausch Health US, LLC$132
- Oyster Point Pharma, Inc.$128
- plus $860 from 14 others
What the payments were for
- Travel & lodging$120%
- Food & beverage$3,480100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 48 | $1,422 |
| AbbVie(2 entities) | 19 | $670 |
| Shire North American Group Inc | 2 | $142 |
| Bausch & Lomb Americas Inc. | 7 | $138 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $132 |
| Oyster Point Pharma, Inc. | 6 | $128 |
| Aerie Pharmaceuticals, Inc. | 3 | $125 |
| LKC Technologies, Inc. | 3 | $124 |
| Dompe US, Inc. | 3 | $115 |
| Tarsus Pharmaceuticals, Inc. | 5 | $113 |
| Novartis | 4 | $87 |
| Amgen(2 entities) | 4 | $70 |
| Octapharma USA, Inc. | 1 | $52 |
| Biotissue Holdings Inc. | 3 | $49 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Rxsight Inc | 2 | $29 |
| Astellas Pharma US Inc | 1 | $16 |
| Glaukos Corporation | 1 | $14 |
| Sight Sciences, Inc. | 1 | $13 |
| Ocular Therapeutix, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$259
- RESTASIS MULTIDOSE$126
- AcrySof IQ PanOptix$123
- XIIDRA$122
- RESTASIS$119
- ARGOS$109
How this compares
$3,492 in reported general payments places this provider in the 75th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 81 | $153,288 |
| LumiganBimatoprost | 193 | $114,945 |
| XiidraLifitegrast | 19 | $36,995 |
| MieboPerfluorohexyloctane/Pf | 35 | $33,974 |
| RestasisCyclosporine | 20 | $29,896 |
| CombiganBrimonidine Tartrate/Timolol | 43 | $17,280 |
| Cyclosporine | 16 | $14,924 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 58 | $12,020 |
| RhopressaNetarsudil Mesylate | 19 | $11,783 |
| Latanoprost | 419 | $6,518 |
| Alphagan PBrimonidine Tartrate | 17 | $5,967 |
| VyzultaLatanoprostene Bunod | 11 | $4,980 |
| Brinzolamide | 18 | $3,609 |
| Prednisolone Acetate | 67 | $3,047 |
| Timolol Maleate | 143 | $2,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $670 | $168,089273 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $113 | $153,28881 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $138 | $75,94965 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $125 | $11,78319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 81 ophthalmology providers in New Mexico.
Other ophthalmology in Las Cruces
- Mark GallardoLas Cruces$1.2M
- Charles SchafferLas Cruces$5K
- Robert VillalobosLas Cruces$2K
- Eric WeberLas Cruces$234
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Paul GulbasRuidoso$14K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.